Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
20.68
+0.18 (0.85%)
Nov 21, 2024, 2:45 PM EST - Market open
Pharvaris Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
82
Market Cap
1.12B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aveanna Healthcare Holdings | 1.98B |
Progyny | 1.14B |
OPKO Health | 711.41M |
Phreesia | 389.96M |
Artivion | 384.90M |
CareDx | 312.78M |
Maravai LifeSciences Holdings | 276.92M |
Ardelyx | 251.85M |
PHVS News
- 7 days ago - Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 9 days ago - Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 5 weeks ago - Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - GlobeNewsWire
- 5 weeks ago - Pharvaris to Host Virtual Investor Event on October 23, 2024 - GlobeNewsWire
- 7 weeks ago - Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop - GlobeNewsWire
- 2 months ago - Pharvaris Provides Business Update and Expands Development Program for Deucrictibant - GlobeNewsWire
- 2 months ago - Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 - GlobeNewsWire
- 2 months ago - Pharvaris Presents Data at the Bradykinin Symposium 2024 - GlobeNewsWire